IN8bio Inc
Company Profile
Business description
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Contact
350 5th Avenue
Suite 5330
New YorkNY10118
USAT: +1 646 600-6438
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
Is this the catalyst US tech giant needs?
stocks
ASX share plunges due to Iran related weakness
stocks
Investors punish this ASX player after acquisition
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,113.40 | 6.40 | 0.07% |
| CAC 40 | 8,189.65 | 69.95 | -0.85% |
| DAX 40 | 23,570.12 | 233.83 | -0.98% |
| Dow JONES (US) | 47,916.57 | 269.23 | -0.56% |
| FTSE 100 | 10,562.54 | 37.99 | -0.36% |
| HKSE | 25,660.85 | 232.69 | -0.90% |
| NASDAQ | 22,902.89 | 80.48 | 0.35% |
| Nikkei 225 | 56,502.77 | 421.34 | -0.74% |
| NZX 50 Index | 13,020.18 | 161.26 | -1.22% |
| S&P 500 | 6,816.89 | 7.77 | -0.11% |
| S&P/ASX 200 | 8,926.00 | 14.20 | 0.16% |
| SSE Composite Index | 3,988.56 | 2.33 | 0.06% |